メタ情報
| meta description平均長 | 303.42 |
|---|
| OGPありページ数 | 84 |
|---|
| Twitterカードありページ数 | 84 |
|---|
内部リンク分析（Internal）
| ユニーク内部リンク数 | 141 |
|---|
| ページあたり内部リンク平均 | 134.2 |
|---|
内部リンク 深さヒストグラム
| キー | 値 |
|---|
| 0 | 430 |
| 1 | 7340 |
| 2 | 3362 |
| 3 | 44 |
| 4 | 11 |
| 5 | 86 |
連絡先候補（Contacts）
このデータの閲覧には会員登録が必要になります。会員登録
キーワード分析（KeywordMap）
ワードクラウド上位
| 語 | 重み |
|---|
| IFRS | 1 |
| statements | 0.762246 |
| non | 0.57377 |
| revenue | 0.42623 |
| measures | 0.42623 |
| looking | 0.410543 |
| its | 0.367903 |
| currency | 0.360656 |
| growth | 0.360173 |
| Dasa | 0.334446 |
| forward | 0.312531 |
| Sophia | 0.311475 |
| company | 0.302185 |
| results | 0.300741 |
| patients | 0.289328 |
| financial | 0.286569 |
| MSK | 0.283459 |
| release | 0.280756 |
| will | 0.280199 |
| expenses | 0.278689 |
| sequencing | 0.270492 |
| management | 0.270357 |
| press | 0.269718 |
| clinical | 0.26922 |
| measure | 0.262295 |
| Amounts | 0.262295 |
| USD | 0.262295 |
| Unaudited | 0.262295 |
| collaboration | 0.261999 |
| care | 0.246358 |
| operating | 0.245902 |
| thousands | 0.243584 |
| future | 0.240118 |
| genomic | 0.234159 |
| more | 0.233284 |
| Digital | 0.229508 |
| testing | 0.226908 |
| new | 0.220742 |
| research | 0.218533 |
| precision | 0.216806 |
| genomics | 0.213942 |
| period | 0.213115 |
| platform | 0.212676 |
| Genetics | 0.210278 |
| across | 0.209996 |
| powered | 0.208909 |
| patient | 0.208909 |
| year | 0.20533 |
| cancer | 0.204748 |
| based | 0.200866 |
共起語上位
| 語1 | 語2 | スコア | 共起ページ数 |
|---|
| party | third | 6.014324 | 850 |
| Diagnostic | Vitro | 5.313566 | 400 |
| EEA | United | 5.268502 | 400 |
| Kingdom | United | 5.268502 | 400 |
| Kingdom | Switzerland | 5.08729 | 400 |
| Add | Modules | 4.897166 | 200 |
| party | trademarks | 4.858793 | 650 |
| otherwise | specified | 4.837325 | 212 |
| clearance | governmental | 4.837325 | 212 |
| Index | galit | 4.791535 | 200 |
| Deficiency | Recombination | 4.791535 | 200 |
| Area | Economic | 4.791535 | 200 |
| Unless | specifically | 4.791535 | 200 |
| identified | specifically | 4.791535 | 200 |
| relationship | sponsorship | 4.791535 | 200 |
| endorsement | sponsorship | 4.791535 | 200 |
| Any | references | 4.791535 | 200 |
| considered | shall | 4.791535 | 200 |
| considered | nominative | 4.791535 | 200 |
| Inherited | Rare | 4.784683 | 204 |
| approval | received | 4.77189 | 212 |
| Homologous | Recombination | 4.768827 | 200 |
| fair | nominative | 4.768827 | 200 |
| appropriate | obtain | 4.750347 | 212 |
| appropriate | product | 4.750347 | 212 |
| Solid | Tumor | 4.746559 | 200 |
| Disorders | Inherited | 4.746119 | 200 |
| governmental | regulatory | 4.739607 | 212 |
| body | regulatory | 4.739607 | 212 |
| specified | unless | 4.731482 | 212 |
| country | residence | 4.731482 | 212 |
| Information | Israel | 4.724716 | 200 |
| property | remain | 4.724716 | 200 |
| between | endorsement | 4.724716 | 200 |
| Modules | Providers | 4.723456 | 150 |
| procedures | unless | 4.709536 | 212 |
| Please | obtain | 4.705177 | 206 |
| France | galit | 4.703282 | 200 |
| DDM | Solution | 4.690879 | 902 |
| law | trademark | 4.68224 | 200 |
| trademark | under | 4.661578 | 200 |
| Diagnostic | Use | 4.655285 | 400 |
| clearance | market | 4.653182 | 212 |
| corresponding | identify | 4.63887 | 200 |
| approval | market | 4.631237 | 212 |
| goods | services | 4.621338 | 200 |
| services | shall | 4.621338 | 200 |
| Add | Disorders | 4.618573 | 200 |
| Economic | European | 4.605629 | 200 |
| applicable | countries | 4.605569 | 212 |
被リンク情報
このデータの閲覧には会員登録が必要になります。会員登録